FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Expires: February 28, 2011
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public
Utility Holding Company Act of 1935 or Section 30(f) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

BVF PARTNERS L P/IL 		2. Issuer Name and Ticker or Trading Symbol

Celera CORP [ CRA ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                      __ X __ 10% Owner
_____ Officer (give title below)      _____ Other (specify below)
(Last)          (First)          (Middle)

900 N. MICHIGAN AVE., SUITE 1100 		3. Date of Earliest Transaction (MM/DD/YYYY)

5/13/2011
(Street)

CHICAGO, IL 60611
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

___ Form filed by One Reporting Person
_ X _ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock   5/13/2011     P    1550   (1) A $8.03   18838767   D   (2)
 
Common Stock   5/13/2011     P    650   (1) A $8.03   18839417   D   (3)
 
Common Stock   5/13/2011     P    6600   (1) A $8.03   18846017   D   (4)
 
Common Stock   5/16/2011     P    30150   (1) A $8.03   18876167   D   (2)
 
Common Stock   5/16/2011     P    19900   (1) A $8.03   18896067   D   (3)
 
Common Stock   5/16/2011     P    80600   (1) A $8.03   18976667   D   (4)
 
Common Stock   5/17/2011     P    35300   (1) A $8.03   19011967   D   (2)
 
Common Stock   5/17/2011     P    24000   (1) A $8.03   19035967   D   (3)
 
Common Stock   5/17/2011     P    92000   (1) A $8.03   19127967   D   (4)
 
Common Stock                  19127967   I   (5) General Partner and Manager of entities with indirect ownership  
Common Stock                  19127967   I   (6) General Partner of entity with indirect ownership  
Common Stock                  19127967   I   (7) Sole shareholder and sole director of entity with indirect ownership  

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Explanation of Responses:
( 1)  Units may represent aggregation of daily trade activity. Details regarding individual execution amounts and prices are available upon request.
( 2)  Shares directly beneficially owned by Biotechnology Value Fund, L.P. ("BVF")
( 3)  Shares directly beneficially owned by Biotechnology Value Fund II, L.P. ("BVF II")
( 4)  The shares of Common Stock are directly beneficially owned by BVF Investments, LLC ("BVFLLC"), a Delaware limited liability company. Pursuant to the operating agreement of BVFLLC, BVF Partners, L.P., a Delaware limited partnership ("Partners") is authorized, among other things, to invest the contributed capital of Samana Capital, L.P., the majority member of BVFLLC, in the shares of Common Stock and other securities and to vote, exercise or convert and dispose of such securities and is entitled to receive fees based on assets under management and, subject to certain exceptions, allocations based on realized and unrealized gains on such assets.
( 5)  The shares of Common Stock are indirectly beneficially owned by Partners. Partners is the general partner of BVF and BVF II, the manager of BVFLLC and the general partner, manager and investment advisor, as the case may be, of the members of BVF X LLC.
( 6)  The shares of Common Stock are indirectly beneficially owned by BVF Inc., a Delaware corporation ("BVF Inc."). BVF Inc. is the general partner of Partners.
( 7)  Mark N. Lampert is the sole shareholder, sole director, and an officer of BVF Inc.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
BVF PARTNERS L P/IL
900 N. MICHIGAN AVE., SUITE 1100
CHICAGO, IL 60611
X

BIOTECHNOLOGY VALUE FUND L P
900 N. MICHIGAN AVE., SUITE 1100
CHICAGO, IL 60611


Direct Beneficial Owner
BVF X LLC
900 N. MICHIGAN AVE., SUITE 1100
CHICAGO, IL 60611


Direct Beneficial Owner
BIOTECHNOLOGY VALUE FUND II LP
900 N. MICHIGAN AVE., SUITE 1100
CHICAGO, IL 60611


Direct Beneficial Owner
BVF INVESTMENTS LLC
900 N. MICHIGAN AVE., SUITE 1100
CHICAGO, IL 60611


Direct Beneficial Owner
BVF INC/IL
900 N. MICHIGAN AVE., SUITE 1100
CHICAGO, IL 60611
X

LAMPERT MARK N
900 N. MICHIGAN AVE., SUITE 1100
CHICAGO, IL 60611
X


Signatures
BVF Partners L.P., By: BVF Inc., its GP, By: /s/ Mark N. Lampert, President 5/17/2011
** Signature of Reporting Person Date

BIOTECHNOLOGY VALUE FUND, L.P. By: BVF Partners L.P., its GP, By: BVF Inc., By: /s/ Mark N. Lampert, President 5/17/2011
** Signature of Reporting Person Date

BIOTECHNOLOGY VALUE FUND II, L.P., By: BVF Partners L.P., its GP, By: BVF Inc., By: /s/ Mark N. Lampert, President 5/17/2011
** Signature of Reporting Person Date

BVF INVESTMENTS, L.L.C., By: BVF Partners L.P., its Manager, By: BVF Inc., By: /s/ Mark N. Lampert, President 5/17/2011
** Signature of Reporting Person Date

BVF X L.L.C., By: Biotechnology Value Fund, L.P., member, By: BVF Partners L.P., its GP, By: BVF Inc., By: /s/ Mark N. Lampert, President 5/17/2011
** Signature of Reporting Person Date

BVF INC., By: /s/ Mark N. Lampert, President 5/17/2011
** Signature of Reporting Person Date

Mark N. Lampert, By: /s/ Mark N. Lampert 5/17/2011
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Celera Corp. (MM) (NASDAQ:CRA)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Celera Corp. (MM) Charts.
Celera Corp. (MM) (NASDAQ:CRA)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Celera Corp. (MM) Charts.